For advanced GC with SRC, patients who have peritoneal recurrence tended to express PD-L1, whereas for advanced GC without SRC, patients with liver metastases tended to have PD-L1 expression, PI3K/AKT pathway mutations and TP53 mutations. This evidence concerns the gene AKT1 and gastric cancer.